These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 17085098)

  • 1. Are there molecular signatures for predicting bladder cancer prognosis?
    Lokeshwar VB
    J Urol; 2006 Dec; 176(6 Pt 1):2347-8. PubMed ID: 17085098
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.
    Lamy A; Gobet F; Laurent M; Blanchard F; Varin C; Moulin C; Andreou A; Frebourg T; Pfister C
    J Urol; 2006 Dec; 176(6 Pt 1):2686-9. PubMed ID: 17085196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.
    Lindgren D; Liedberg F; Andersson A; Chebil G; Gudjonsson S; Borg A; Månsson W; Fioretos T; Höglund M
    Oncogene; 2006 Apr; 25(18):2685-96. PubMed ID: 16532037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    Burger M
    Eur Urol; 2009 Mar; 55(3):657. PubMed ID: 18584941
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment on: FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    Malats N; Real FX
    Eur Urol; 2009 Mar; 55(3):658. PubMed ID: 18584942
    [No Abstract]   [Full Text] [Related]  

  • 7. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Montironi R; Scarpelli M; Lopez-Beltran A; Cheng L
    Eur Urol; 2009 Nov; 56(5):846-7. PubMed ID: 18945536
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial comment on: Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Kruck S; Sievert KD
    Eur Urol; 2009 Nov; 56(5):845-6. PubMed ID: 18945542
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment on: Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study.
    Montironi R; Lopez-Beltran A; Cheng L
    Eur Urol; 2008 Oct; 54(4):843-4. PubMed ID: 18166261
    [No Abstract]   [Full Text] [Related]  

  • 11. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome.
    Lindgren D; Frigyesi A; Gudjonsson S; Sjödahl G; Hallden C; Chebil G; Veerla S; Ryden T; Månsson W; Liedberg F; Höglund M
    Cancer Res; 2010 May; 70(9):3463-72. PubMed ID: 20406976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC.
    Scher HI
    J Urol; 1995 Nov; 154(5):1969. PubMed ID: 7563393
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment.
    Gonzalgo ML
    J Urol; 2009 Sep; 182(3):913. PubMed ID: 19616241
    [No Abstract]   [Full Text] [Related]  

  • 15. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours.
    van Oers JM; Zwarthoff EC; Rehman I; Azzouzi AR; Cussenot O; Meuth M; Hamdy FC; Catto JW
    Eur Urol; 2009 Mar; 55(3):650-7. PubMed ID: 18584939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
    van Rhijn BW; Lurkin I; Radvanyi F; Kirkels WJ; van der Kwast TH; Zwarthoff EC
    Cancer Res; 2001 Feb; 61(4):1265-8. PubMed ID: 11245416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 gene mutation in recurrent superficial bladder cancer.
    Yoshimura I; Kudoh J; Saito S; Tazaki H; Shimizu N
    J Urol; 1995 May; 153(5):1711-5. PubMed ID: 7715016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
    Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
    Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic biomarkers for early detection, therapeutic effectiveness and relapse monitoring in bladder cancer.
    Dumache R; David D; Kaycsa A; Minciu R; Negru S; Puiu M
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):163-7. PubMed ID: 21682190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.